论文部分内容阅读
目的:探讨联合检测血清Cyfra 21-1、CK19-2G2在非小细胞肺癌患者中的诊断。方法:采用化学发光免疫法检测92例非小细胞肺癌患者、83例肺部良性疾病患者和90例健康体检者血清Cyfra 21-1、CK19-2G2的浓度,并判断两者的相关性。比较单独与联合检测Cyfra21-1、CK19-2G2对于诊断非小细胞肺癌的灵敏度和特异性。结果:非小细胞肺癌组血清Cyfra 21-1、CK19-2G2水平显著高于肺部良性疾病组和健康对照组(P<0.01);非小细胞肺癌患者血清Cyfra 21-1与CK19-2G2水平呈正相关性(P<0.05)。两者联合诊断非小细胞肺癌的灵敏度为82.7%、特异性为78%。结论:Cyfra 21-1、CK19-2G2是有效的诊断非小细胞肺癌的肿瘤标志物。血清Cyfra 21-1、CK19-2G2水平在非小细胞肺癌的诊断中有临床应用价值,两者联合检测的灵敏度和特异性高。
Objective: To explore the combined detection of serum Cyfra 21-1, CK19-2G2 in patients with non-small cell lung cancer diagnosis. Methods: The serum levels of Cyfra 21-1 and CK19-2G2 in 92 patients with non-small cell lung cancer, 83 patients with benign lung diseases and 90 healthy controls were detected by chemiluminescence immunoassay and their correlations were determined. To compare the sensitivity and specificity of Cyfra21-1 and CK19-2G2 alone and in combination for the diagnosis of non-small cell lung cancer. Results: Serum levels of Cyfra 21-1 and CK19-2G2 in non-small cell lung cancer were significantly higher than those in benign lung disease group and healthy controls (P <0.01). Serum levels of Cyfra 21-1 and CK19-2G2 in non-small cell lung cancer There was a positive correlation (P <0.05). The sensitivity and specificity of the combined diagnosis of non-small cell lung cancer was 82.7% and 78% respectively. Conclusion: Cyfra 21-1 and CK19-2G2 are effective tumor markers for the diagnosis of non-small cell lung cancer. The serum levels of Cyfra 21-1 and CK19-2G2 have clinical value in the diagnosis of non-small cell lung cancer, and their combined detection has high sensitivity and specificity.